News

May 19, 2013

German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRIŽ (pixantrone)

May 14, 2013

Cell Therapeutics to Present at Upcoming Investor Conferences

view all news releases

Events

June 4, 2013

Cell Therapeutics, Inc. at Jefferies Global Healthcare Conference

May 21, 2013

Cell Therapeutics, Inc. at UBS Global Healthcare Conference

view all events

Pixuvri® Approved in E.U.

PIXUVRI is the only medicine approved as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell lymphomas in the E.U.

Download Summary of Product Characteristics and Package Insert

Pixantrone is marketed in the E.U. as PIXUVRI | Learn more

Resources

patient & caregiver information medical professionals information

Pipeline

Our late-stage development pipeline addresses a full complement of blood-related cancers.

learn about our oncology pipeline

Video Highlights

Our Mission
 

James Bianco, M.D., President and CEO, explains CTI's mission to develop less toxic and more effective therapies for people living with cancer.
 

You are now leaving website and entering the website.

If you would like to continue, click Continue.

CancelContinue